KCNA3 and epilepsy: Using a similar strategy, a recent study (Ibhazehiebo et al., 2018) identified an approved anti-cancer drug, vorinostat, which improved mitochondrial bioenergenics and seizures in a potassium channel gene knockdown epilepsy model (kcn1a).